{
 "PrintNo":"A8576","Session":2025,"Chamber":"ASSEMBLY","BillType":"Assembly","Published":"2025-05-21T14:40:41.053123Z",
 "Status":"IN_ASSEMBLY_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2025-05-21","Committee":"Health"}],
 "Actions":[{"Text":"REFERRED TO HEALTH","Date":"2025-05-21","Chamber":"ASSEMBLY"}],
 "Sponsors":[
  {"ID":1482,"Name":"Anna Kelles","Short":"KELLES"},{"ID":1488,"Name":"Jonathan Rivera","Short":"RIVERA"},
  {"ID":655,"Name":"Maritza Davila","Short":"DAVILA"},{"ID":1478,"Name":"Chris Burdick","Short":"BURDICK"},
  {"ID":907,"Name":"Jo Anne Simon","Short":"SIMON"},{"ID":1144,"Name":"Harvey Epstein","Short":"EPSTEIN"},
  {"ID":520,"Name":"Linda Rosenthal","Short":"ROSENTHAL"},{"ID":576,"Name":"Donna Lupardo","Short":"LUPARDO"},
  {"ID":1468,"Name":"Jessica Gonzalez-Rojas","Short":"GONZALEZ-ROJAS"},{"ID":540,"Name":"Amy Paulin","Short":"PAULIN"},
  {"ID":898,"Name":"Rodneyse Bichotte Hermelyn","Short":"BICHOTTE HERMELYN"},
  {"ID":675,"Name":"Phil Steck","Short":"STECK"},{"ID":571,"Name":"Albert A. Stirpe","Short":"STIRPE"},
  {"ID":1148,"Name":"Doug Smith","Short":"SMITH"},{"ID":1257,"Name":"Karines Reyes","Short":"REYES"},
  {"ID":1474,"Name":"Phara Souffrant Forrest","Short":"FORREST"},{"ID":474,"Name":"Charles Lavine","Short":"LAVINE"},
  {"ID":1476,"Name":"Chantel Jackson","Short":"JACKSON"},{"ID":488,"Name":"Andrew Hevesi","Short":"HEVESI"},
  {"ID":533,"Name":"Jeffrey Dinowitz","Short":"DINOWITZ"},{"ID":1469,"Name":"Zohran Mamdani","Short":"MAMDANI"},
  {"ID":519,"Name":"Deborah Glick","Short":"GLICK"},{"ID":670,"Name":"Angelo Santabarbara","Short":"SANTABARBARA"},
  {"ID":1147,"Name":"Steve Stern","Short":"STERN"},{"ID":1537,"Name":"Dana Levenberg","Short":"LEVENBERG"},
  {"ID":1477,"Name":"Amanda Septimo","Short":"SEPTIMO"}
 ],
 "Title":"Preserves access to affordable drugs",
 "Summary":"Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.",
 "LawSection":"Public Health Law","LawCode":"Add Art 2-A Title IV §§282 & 283, Pub Health L",
 "ActClause":"AN ACT to amend the public health law, in relation to preserving access to affordable drugs",
 "SameAsPrintNo":"S3203-2025","PreviousVersions":["A7245-2021","A7465-2023"]
}